Strategic Partnership to Expand Clinical Research Offerings
Sofia/Wayne - Bulgarian AbC.R.O., Inc. signed a strategic partnership agreement with Covalent Group, Inc. in January to expand clinical research offerings and capabilities in Eastern Europe. The terms of the agreement provide for a well-defined regional relationship between the parties for the marketing and delivery of clinical development services on a global basis and for the alignment of standard operating procedures and information technologies.
AbC.R.O., Inc., operates exclusively in South-eastern Europe with operational headquarters in Sofia, Bulgaria, and has additional offices in Romania and Croatia, providing regional coverage in Serbia and Slovenia, too. The specialized clinical research organization (CRO) offers high quality clinical trial services in the phases II to IV in therapeutic areas including oncology, cardiology, dermatology, diabetes, neurology, infectious diseases, and respiratory illnesses in South-eastern Europe to international pharmaceutical and biotechnology firms. Dana Leff, Chief Executive Officer of AbC.R.O., Inc. remarked, “AbC.R.O. is looking forward to a successful collaboration with Covalent. Southeastern Europe provides an exciting option for clients to optimize the country mix for their global clinical trials.”
Covalent, a US-headquartered full-service CRO specializing in the design and management of complex clinical trials for the pharmaceutical and biotechnology industries, has clinical operations in 18 countries in North America, Western Europe, and Scandinavia.